SHREDZ: Human Clinical Research on Combined Lipotropic & Metabolic Cofactor Compounds

Abstract: SHREDZ contains a combination of lipotropic nutrients and metabolic cofactors evaluated in human clinical research for their roles in fatty acid transport, methylation pathways, hepatic lipid metabolism, mitochondrial bioenergetics, redox regulation, and insulin sensitivity. This article summarizes peer-reviewed human data on each compound and examines potential mechanistic synergy when studied collectively.

---

Ingredient-Level Clinical Evidence

---

L-Carnitine (Fatty Acid Transport & Mitochondrial Function)

L-Carnitine facilitates transport of long-chain fatty acids into mitochondria via the carnitine shuttle system (CPT-I and CPT-II), enabling beta-oxidation and ATP production.

Human research has evaluated L-Carnitine in:

• Cardiac remodeling and heart failure cohorts
• Exercise performance and recovery studies
• Metabolic syndrome investigations
• Fatigue-related clinical populations

Observed biomarkers:

• Improved fatty acid oxidation markers
• Altered lactate accumulation
• Enhanced mitochondrial substrate utilization

References: Malaguarnera M. et al., Am J Clin Nutr. DiNicolantonio JJ. et al., Mayo Clin Proc.

---

Vitamin B12 (Methylcobalamin)

Vitamin B12 functions as a cofactor for methionine synthase, supporting homocysteine remethylation and DNA synthesis.

Human studies have evaluated B12 in:

• Neurological function
• Erythropoiesis
• Homocysteine regulation
• Methylation disorders

Deficiency states are associated with impaired energy metabolism and neurological dysfunction.

---

Vitamin B6 (Pyridoxal-5-Phosphate)

Vitamin B6 acts as a coenzyme in over 100 enzymatic reactions including amino acid metabolism, neurotransmitter synthesis, and glycogen breakdown.

Clinical investigations show involvement in:

• Neurotransmitter regulation (serotonin, dopamine synthesis pathways)
• Homocysteine metabolism
• Energy substrate conversion

---

Inositol

Inositol functions in cellular signaling and lipid metabolism. Human studies have examined inositol in metabolic and hepatic contexts.

Research areas include:

• Insulin signaling modulation
• Hepatic fat accumulation markers
• Lipid profile changes

Reference: Croze ML & Soulage CO. Biochimie.

---

Methionine (Methyl Donor & Lipotropic Factor)

Methionine is an essential amino acid and precursor to S-adenosylmethionine (SAMe), a key methyl donor involved in hepatic lipid metabolism and detoxification pathways.

Human research links methionine metabolism to:

• Methylation efficiency
• Hepatic fat export mechanisms
• Homocysteine balance

---

Choline Bitartrate

Choline contributes to phosphatidylcholine synthesis and very-low-density lipoprotein (VLDL) export from liver tissue.

Human deficiency studies demonstrate:

• Hepatic steatosis development
• Elevated liver enzymes
• Impaired lipid transport

Clinical research supports its role in lipid transport and structural cell membrane integrity.

Reference: Zeisel SH. Annu Rev Nutr.

---

Alpha Lipoic Acid (ALA)

Alpha Lipoic Acid functions as a mitochondrial cofactor and antioxidant. It has been evaluated in human trials for metabolic regulation and oxidative stress modulation.

Human research findings include:

• Improved insulin sensitivity in certain populations
• Reduction in oxidative stress markers
• Support of mitochondrial enzyme complexes

Reference: Shay KP et al., Biochim Biophys Acta.

---

Mechanistic Synergy

When examined collectively, these compounds interact across interconnected metabolic pathways:

• Fatty Acid Transport: L-Carnitine facilitates mitochondrial entry of fatty acids.
• Methylation Cycle Support: B12, B6, Methionine, and Choline contribute to homocysteine regulation and methyl donor balance.
• Hepatic Lipid Export: Choline and Methionine support VLDL-mediated lipid transport.
• Redox Regulation: Alpha Lipoic Acid modulates oxidative stress affecting mitochondrial efficiency.
• Cellular Signaling: Inositol influences insulin and lipid metabolism pathways.

Human clinical literature supports each compound independently. Synergistic evaluation remains mechanistically plausible based on overlapping metabolic roles but is dependent on context, dosing, and study population.

---

Clinical Domains of Investigation

• Metabolic syndrome
• Non-alcoholic fatty liver disease (NAFLD)
• Exercise physiology
• Cardiovascular remodeling
• Homocysteine-associated vascular risk

---

Scientific Notice

This article summarizes peer-reviewed human clinical literature for educational purposes only. Products are designated for laboratory research use only and are not intended for human or veterinary consumption. Nothing within this publication constitutes medical advice, diagnosis, or treatment guidance.